Biophytis Expands Recruitment for Part 2 of Phase 2-3 COVA Trial in France and Belgium

 

• Clinical centers in France and Belgium will begin recruitment for Part 2 of the COVA Study following authorization from Regulatory Authorities

• These approvals follow the previous authorizations obtained from Brazil and the United States in most clinical centers

• Interim Analysis of Part 1 is expected in Q1 2021

• Results from the full study (Part 1 and Part 2) are expected in Q2 2021

Biophytis SA (NasdaqGS: BPTS; Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces that patient recruitment will begin in France and Belgium for Part 2 of its COVA Study assessing Sarconeos (BIO101) as a potential treatment for acute respiratory failure associated with COVID-19.

https://finance.yahoo.com/news/biophytis-announces-expansion-patient-recruitment-070000288.html